APONTIS PHARMA and Zentiva Forge Strategic Partnership

APONTIS PHARMA AG, a leader in Single Pill combinations in Germany, has entered into a strategic partnership with Zentiva, a prominent European pharmaceutical platform. Zentiva plans to launch a voluntary public purchase offer, valuing APONTIS PHARMA shares at EUR 10.00 each, reflecting a 52.9% premium on the closing price as of 15 October 2024.

The agreement aims to foster APONTIS PHARMA's growth leveraging Zentiva's resources and market presence. Zentiva intends to acquire a majority stake, needing a minimum acceptance of 65%. It has already secured 37.5% of shares from the main shareholder.

The Executive and Supervisory Boards of APONTIS PHARMA have endorsed the offer, highlighting it as beneficial for the company's stakeholders. The collaboration seeks to enhance APONTIS PHARMA’s product pipeline, especially in cardiovascular treatments, while considering international expansion.